Accurately determine risk of recurrence with Prosigna
Prosigna Scores correlate with 10-year probability of distant recurrence
- The Prosigna Scores for a cohort of postmenopausal women with hormone receptor–positive, early-stage breast cancer were compared to distant recurrence-free survival (DRFS) following surgery and treatment with 5 years of adjuvant endocrine therapy followed by 5 years of observation (see Data summary)
- This study resulted in a model relating the Prosigna Score to the probability of distant recurrence in 2 tested patient populations (node negative and node positive), including a 95% confidence interval
Reference: 1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013.